Abstract 359P
Background
In particular, cancer patients with minor children encounter various problems, including family, parenting, employment, and economic burdens. This study aimed to examine the economic burden among cancer patients with minor children.
Methods
This was a sub-analysis of a cross-sectional web-based survey. Cancer patients with minor children were recruited from an online community and asked to answer a questionnaire.The proportion of subjects experiencing economic burden, and factors associated with economic burden were analyzed.
Results
A total of 368 subjects were eligible [19% male, mean age (SD): 43.0 years (5.8)]. The most common primary cancer site was breast (34%), followed by the colorectal region (12%), and gynecological organs (11%). Among the subjects, 127 (34%) experiencedeconomic burden. Univariate analyses showed that advanced stage (38% in subjects experiencing economic burden vs. 22% in subjects not experiencingeconomic burden, p = 0.002), presence of metastases (51% vs. 35%, p = 0.004), cancer recurrence (24% vs. 14%, p = 0.032), using anti-tumor drugs (47% vs. 33%, p = 0.010), having a full-time job (24% vs. 48%, p < 0.001), change of work situation (76% vs. 44%, p < 0.001), and decrease of income (76% vs. 38%, p < 0.001) were associated with patients experiencingeconomic burden.
Conclusions
The present study showed that advanced stage, anti-tumor treatment, and work situation were associated with economic burden among cancer patients with minor children.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Center.
Funding
Takeda Science Foundation.
Disclosure
K. Kosugi: Honoraria (self): Mundipharma. D. Fujisawa: Honoraria (self): Pfeizer, Mochida, Tanabe-Mitsubishi, Shionogi, Meiji Pharma, MSD. T. Kawaguchi: Honoraria (self): Chugai. K. Izumi: Full / Part-time employment: Medilead Inc. J. Takehana: Full / Part-time employment: Medilead Inc. Y. Matsumoto: Honoraria (self): Kyowa Kirin; Honoraria (self): Shionogi; Honoraria (self): Terumo; Honoraria (self): Meiji Seika Pharma; Honoraria (self): Hisamitsu Pharmaceutical; Honoraria (self): Eisai; Honoraria (self): Pfizer; Honoraria (self): AstraZeneca; Honoraria (self): Mundipharma; Honoraria (self): Daiichi-Sankyo. All other authors have declared no conflicts of interest.
Resources from the same session
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract